Esophageal Squamous Cell Carcinoma Pipeline Looks Promising as 45+ Companies Working in the Domain, Assesses DelveInsight

The prevalence of Esophageal Squamous Cell Carcinoma has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of cancer and the increase in research & development. The Companies developing the potential therapies in the last stage of development include Sunshine Lake Pharma Co., Jiangsu HengRui Medicine Co., Roche, and several others.

LAS VEGAS, Oct. 25, 2022 /PRNewswire/ -- DelveInsight's 'Esophageal Squamous Cell Carcinoma Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline esophageal squamous cell carcinoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the esophageal squamous cell carcinoma pipeline domain.

Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report

• DelveInsight's esophageal squamous cell carcinoma pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for esophageal squamous cell carcinoma treatment. 
• Leading esophageal squamous cell carcinoma companies such as Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences., Leap Therapeutics, Inc. and others are evaluating novel esophageal squamous cell carcinoma drugs candidate to improve the treatment landscape.
• Key esophageal squamous cell carcinoma pipeline therapies in various stages of development include Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab,   SI B001,Apatinib,  AP 203, QEQ278, JAB-3312, DKN-01, and others.
• In August 2022, BeiGene announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) had accepted a supplemental biologics license application (sBLA) for tislelizumab in combination with chemotherapy as first-line treatment in patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
• In July 2022, Novartis announced results from the Phase-III Rationale 306 trial showing tislelizumab plus chemotherapy significantly improved the Overall Survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic Esophageal Squamous Cell Carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 months (CI, 9.3-12.1 months) in patients receiving chemotherapy plus placebo and reduced the risk of death by 34 per cent (hazard ratio=0.66; CI, 0.54-0.80, p<0.0001). In collaboration with BeiGene, these data were presented during a late-breaking oral session at the 2022 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer.
• In June 2022, Innovent Biologics Inc. and Eli Lilly and Company announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) had approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
• In May 2022, Bristol Myers Squibb, announced that the U.S. Food and Drug Administration (FDA) had approved both Opdivo (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status. The approvals are based on the Phase III CheckMate -648 trial, which evaluated Opdivo in combination with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) each compared to chemotherapy alone (n=324), and was the largest Phase III trial of immunotherapy in first-line ESCC.
• In May 2022, Shanghai Junshi Biosciences Co., Ltd, announced that the China National Medical Products Administration (NMPA) had approved the supplemental new drug application (sNDA) for toripalimab in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC). The sNDA was accepted by the NMPA in July 2021. This is the fifth indication approved for toripalimab in China and will benefit Chinese patients with advanced ESCC.
• In April 2022, BeiGene, Ltd. announced that the China National Medical Products Administration (NMPA) had granted approval to BeiGene's anti-PD-1 antibody, tislelizumab, as a treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have disease progression or are intolerant to first-line standard chemotherapy.
• In January 2022, Lyell Immunopharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that the company is developing in collaboration with GSK.

Request a sample and discover the recent advances in esophageal squamous cell carcinoma treatment @Esophageal Squamous Cell Carcinoma Pipeline Report

The esophageal squamous cell carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage esophageal squamous cell carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the esophageal squamous cell carcinoma pipeline landscape. 

Esophageal Squamous Cell Carcinoma Overview

Esophageal Squamous Cell Carcinoma is the most common type of esophageal cancer worldwide. Clinical management of ESCC remains difficult, and the disease currently lacks approved targeted therapeutics. The average age of onset of ESCC is between the ages of 60 and 70 years, and it is more common in men. It is usually asymptomatic until the disease progresses, with the most common presenting esophageal squamous cell carcinoma symptoms being dysphagia (first with solids, then fluids) and weight loss. 

Odynophagia, hoarseness of voice, coughing, or chest pain are less common presenting esophageal squamous cell carcinoma symptoms. Tumors are most commonly found in the middle and upper thirds of the esophagus. The precise cause is unknown. The primary risk factors are cigarette smoking and alcohol abuse.

Find out more about esophageal squamous cell carcinoma treatment @Esophageal Squamous Cell Carcinoma Medication 

A snapshot of the Esophageal Squamous Cell Carcinoma Pipeline Drugs mentioned in the report:

Learn more about the emerging esophageal squamous cell carcinoma pipeline therapies @Esophageal Squamous Cell Carcinoma Clinical Trials

Esophageal Squamous Cell Carcinoma Therapeutics Assessment

The esophageal squamous cell carcinoma pipeline report proffers an integral view of the esophageal squamous cell carcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Inhalation, Intravenous, Oral, Intranasal, Parenteral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
• Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Epidermal growth factor receptor antagonists, DNA topoisomerase I inhibitors, Tubulin polymerization inhibitors, Cell death stimulants, Mitosis inhibitor.
• Key Esophageal Squamous Cell Carcinoma Companies: Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc. and others
• Key Esophageal Squamous Cell Carcinoma Pipeline Therapies: Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S 095033, INCB099318, RO7121661, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab,   SI B001,Apatinib,  AP 203, QEQ278, JAB-3312, DKN-01 and others.

Dive deep into rich insights for drugs for esophageal squamous cell carcinoma treatment, visit @Immunotherapy for Esophageal Squamous Cell Carcinoma Treatment

Table of Contents

For further information on the esophageal squamous cell carcinoma pipeline therapeutics, reach out @Esophageal Squamous Cell Carcinoma Drugs

Related Reports

Esophageal Squamous Carcinoma Market

Esophageal Squamous Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal squamous carcinoma companies, including BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others.

Esophageal Squamous Cell Carcinoma Epidemiology

Esophageal Squamous Cell Carcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted esophageal squamous cell carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Esophageal Cancer Pipeline

Esophageal Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key esophageal cancer companies, including Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., among others.

Esophageal Cancer Market

Esophageal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal cancer companies including Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, among others.

Esophageal Cancer Epidemiology Forecast

Esophageal Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted esophageal cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Other Trending Reports

Goitre Market |  Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg